Proliferative vitreoretinopathy
Information
- Disease name
- Proliferative vitreoretinopathy
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00000140 | Completed | Phase 3 | The Silicone Study | September 1985 | |
| NCT00373282 | Completed | Phase 3 | Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy | June 2001 | June 2003 |
| NCT01255293 | Completed | N/A | Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments | November 2010 | October 2012 |
| NCT01445028 | Completed | Phase 4 | Isotretinoin for Proliferative Vitreoretinopathy | September 2011 | August 2015 |
| NCT01995045 | Completed | Phase 4 | Postoperative Pain Control Following Vitreoretinal Surgery | July 2012 | December 2015 |
| NCT02192970 | Completed | Phase 2 | Bevacizumab Against Recurrent Retinal Detachment | January 21, 2015 | November 11, 2019 |
| NCT03727776 | Completed | Early Phase 1 | Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR) | August 19, 2019 | July 7, 2023 |
| NCT04136366 | Completed | Phase 3 | The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy | November 15, 2019 | June 14, 2022 |
| NCT04490876 | Completed | Outcomes of Extensive Brilliant Blue G-Assisted Internal Limiting Membrane Peeling in Proliferative Vitreoretinopathy | July 20, 2020 | July 25, 2020 | |
| NCT04891991 | Completed | Phase 2 | Intravitreal Infliximab for Proliferative Vitreoretinopathy | November 26, 2021 | November 10, 2023 |
| NCT06166914 | Completed | N/A | Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment | October 21, 2021 | May 21, 2023 |
| NCT06033703 | Not yet recruiting | Phase 1/Phase 2 | Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment | February 2024 | December 2024 |
| NCT05538156 | Not yet recruiting | N/A | Internal Limiting Membrane Peeling in Retinal Detachment Surgery | September 2022 | December 2027 |
| NCT06425419 | Not yet recruiting | Phase 1 | The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy | July 1, 2024 | March 1, 2026 |
| NCT06289205 | Recruiting | Phase 1/Phase 2 | "Comparing Methotrexate Usage Techniques to Prevent Proliferative Vitreoretinopaty After Retinal Detachment Vitrectomy" | March 2024 | May 2025 |
| NCT05561569 | Recruiting | N/A | Air Versus Gas Tamponade in Primary Retinal Detachment | September 26, 2022 | July 1, 2023 |
| NCT05660447 | Recruiting | Phase 2/Phase 3 | A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR | February 6, 2023 | December 31, 2023 |
| NCT04482543 | Unknown status | Phase 2/Phase 3 | Repeated Methotrexate for Proliferative Vitreoretinopathy Grade C | August 1, 2020 | September 1, 2021 |
| NCT04580147 | Unknown status | Phase 2 | Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair | October 15, 2020 | December 15, 2023 |
| NCT00370760 | Unknown status | Phase 3 | Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) | September 2006 | |
| NCT00371020 | Unknown status | Phase 3 | The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR | February 2005 | July 2007 |
| NCT04682054 | Unknown status | N/A | Molecular Taxonomy of Surgically-harvested Ocular Tissues Defined by Single-cell Transcriptomics | January 15, 2021 | December 31, 2021 |
| NCT02748421 | Unknown status | N/A | Optical Coherence Tomography - Rescan During Dissection of Macular Membranes | May 2016 | July 2017 |
| NCT04830878 | Withdrawn | Phase 1 | Methotrexate For The Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients | April 2021 | April 2024 |